years before being treated with radiosurgery at our institution. The locations and volumes of the AVMs are summarized in Tables 2 and 3 . The mean nidus diameter was 2.7 cm (range 0.6-6.2 cm). Ninety AVMs had a volume of 10 cm 3 or less and 31 had a volume over 10 cm 3 . The patients with smaller AVMs did not differ significantly from those who had larger AVMs with respect to age (analysis of variance test (ANOVA)), history of hemorrhage, headache, neurological deficit, or AVM location (chi-square with Yate's correction). Patients with AVMs over 10 cm 3 did have a higher incidence of pretreatment seizures (p Ͻ 0.01). Forty-five AVMs (37%) were judged to have an unacceptable risk of death or serious neurological morbidity if treated with contemporary microsurgical techniques.
Radiosurgical Planning and Dosimetry
Stereotactic biplane cerebral angiography using magnification and subtraction techniques was used to define the nidus and to localize the irradiation targets in every case. Magnetic resonance (MR) imaging or, when that was contraindicated by the presence of intracranial vascular clips, computerized tomography (CT) was used as an adjunct in treatment planning for large, complex, or critically located AVMs. Our dose-volume protocol is shown in Table 4 . This protocol was based upon the results of earlier radiosurgical series and was guided by mathematical models designed to limit the risk of radiation-induced permanent neurological complications to 3% or less. 5, 10 Early in our experience, partial coverage of the nidus as a deliberate strategy to stage treatment in two sessions was performed in two patients (1.6% of the series) with large, complex, multicompartmental AVMs. Beginning in 1993, patients with small, previously ruptured AVMs having a volume of 2.1 cm 3 or less (diameter ≤ 1.6 cm) were treated with a dose of 22 Gy to the margin. The mean dose administered to the AVM margin was 18 Gy (range 16-22 Gy) at the 50% to 70% isodose line. The mean central dose was 35 Gy (range 22-44 Gy). The mean number of irradiation isocenters was four (range one-11). The difference between the mean number of isocenters used to treat AVMs of 10 cm 3 or less (3.1Ϯ 2.2 isocenters) differed significantly from the number of isocenters required to cover AVMs of over 10 cm 3 (7.3 Ϯ 1.5 isocenters) (ANOVA, p Ͻ 0.0001).
Results

Clinical and Neurological Outcome
Clinical follow-up monitoring of all 121 patients for between 12 and 60 months after treatment revealed that 83 patients (69%) remained neurologically stable and that 22 patients (18%) were improved either objectively, due to reduction or elimination of seizures, or subjectively, due to relief of severe vascular headaches (Table 5) . Six patients, one with an AVM larger than 10 cm 3 and five with AVMs smaller than 10 cm 3 , developed new neurological deficits directly attributable to treatment. This represented 5.5% of patients with smaller AVMs (five of 90 cases) and 3.2% of patients with larger AVMs (one of 31 cases), a difference that was not statistically significant (Fisher's exact test, p = 1.000). Two of the treatment-induced deficits occurred after repeat radiosurgery of incompletely obliterated AVMs in functional brain regions (dorsal midbrain and internal capsule). The risk of a radiosurgically induced neurological deficit after retreatment versus first treatment also was not statistically significant (Fisher's exact test, p = 0.097).
Four patients with previously unruptured AVMs each had a single nonfatal hemorrhage between 9 and 30 months after radiosurgery. The AVM volumes were 10 cm 3 or less in three of these and over 10 cm 3 in one patient. The hemorrhages in two patients required surgery for removal of the hematoma and malformation. One patient, as a result of her hemorrhage, sustained a neurological deficit that persisted after surgery. Angiography in the third patient showed complete obliteration of the nidus on two studies separated by 6 weeks. This suggested that the hemorrhage occurred during the final stages of AVM obliteration. The fourth patient to experience a nonfatal hemorrhage had a large (> 10 cm 3 ) AVM that bled into the lateral ventricle and did not cause a neurological deficit. The patient refused further surgery beyond placement of a temporary ventriculostomy.
One patient with a previously unruptured AVM that was less than 10 cm 3 in volume and located in the thalamus died from hemorrhage of the AVM 15 months after treatment. Two other patients with small, previously ruptured AVMs in the basal ganglia and thalamus, respectively, suffered fatal second hemorrhages 3 months after radiosurgery. The observed differences in the occurrence of posttreatment hemorrhages between patients with large versus small AVMs (first hemorrhage, one of 18 versus four of 50; repeat hemorrhage, none of 13 versus two of 40; and total hemorrhages, one of 31 versus six of 90) were not statistically significant (Fisher's exact test twosided p values = 1.000, 1.000, and 0.676, respectively). Three patients died of causes not directly related to their AVMs or treatment.
Angiographic Obliteration
Fifty-one patients underwent cerebral angiography between 12 and 44 months after radiosurgery ( ) that were not obliterated by 3 years after radiosurgery despite dose plans that were judged to have covered the nidus (eight in our series and two initially treated elsewhere), six were found in retrospect to have been treated incompletely. The single AVM that was greater than 10 cm 3 was removed surgically on an elective basis. Retrospective analysis of the radiosurgical dose plan revealed that a portion of the nidus was outside the treatment isodose. Analysis of the original dose plans in the other 3-year treatment failures revealed that a portion of the nidus was outside the prescribed isodose line in three more of our cases and in the two patients with AVMs of 10 cm 3 or less who had undergone previous gamma knife radiosurgery elsewhere (Fig.  1) . Insufficient data were available to evaluate the treatment plans in the two patients who had undergone previous proton beam therapy elsewhere.
Time Course of AVM Shrinkage
At least one follow-up imaging study was available for 106 (88%) of the 121 patients in this series. To obtain conservative statistical estimates, any patient who underwent an imaging study (CT scan, MR image, or angiogram) that showed findings other than complete obliteration by conventional angiography was counted as having a live AVM during that time interval. Thus, only AVMs that were angiographically obliterated were counted in the numerator for statistical calculations. Figure 2 illustrates the Kaplan-Meier 8 estimated angiographic obliteration rates as a function of time and nidus volume. The estimated AVM obliteration rates for all 106 patients with follow-up imaging at 2, 3, and 4 years, respectively, were 27%, 65%, and 82%. The corresponding estimated 2-, 3-, and 4-year obliteration rates for AVMs of 10 cm 3 or less were 31%, 64%, and 82%. The 2-and 3-year estimated obliteration rates for AVMs greater than 10 cm 3 were 13% and 71%, respectively.
Discussion
Clinical Outcome
In our series and in others, 7, 12 the majority of patients remained clinically stable or improved throughout the latency period before eventual AVM obliteration ( Table 5 ). The neurological morbidity rate directly related to treatment in our 121 patients was 5%. One additional patient (0.8%), who sustained a neurological deficit as a consequence of a posttreatment hemorrhage, brought the total neurological management morbidity to 5.8%. Three other nonfatal hemorrhages did not result in new, permanent neurological deficits. Three fatal hemorrhages in patients with deep AVMs yielded a mortality rate of 2.5%. These figures are comparable to other radiosurgical series and to comprehensive surgical series that included a similar proportion of deeply situated AVMs.
1-4,6,7,9,11-13,15 Because radiosurgery does not result in an immediate cure, the risk of a first or repeat hemorrhage from the AVM probably remains unaltered until complete obliteration occurs.
We observed no statistically significant differences on the basis of AVM size in the occurrence of a first hemorrhage after radiosurgery of an unruptured AVM or in the occurrence of a repeat hemorrhage after radiosurgery of a previously ruptured AVM. Analysis of our series and others over a longer period will be necessary to determine whether these findings are reproducible or merely a consequence of a limited sample size. One further observation is that radiation-induced complications did not appear to be more frequent in patients with AVMs larger than 10 cm 3 that were treated using our dose/volume schema.
Obliteration Rate of AVMs
The overall AVM obliteration rate in this series (74.5%) was within the range reported by other investigators using the Leksell gamma unit (59%-85%) 2, 6, 9, [11] [12] [13] linear-accelerator (LINAC)-based radiosurgical systems (66%-81%). [1] [2] [3] [4] 7 Stratification of obliteration rate data by AVM volume was performed by investigators who used the Leksell gamma unit in the United States 11, 12 and by Kemeny, et al., 9 in an early report from Sheffield, England. Although some reports 12 showed an apparent relationship between AVM volume and the 2-year or later obliteration rate for AVMs smaller than 10 cm 3 , the Sheffield group found no such correlation in AVMs up to 3.0 cm in diameter or larger (volume ≥ 14.1 cm   3 ). Both Colombo and coworkers 3, 4 and Betti, et al., 1 reported a correlation between smaller nidus volumes and higher 2-year AVM obliteration rates in patients treated using a variety of LINAC-based techniques. Friedman and Bova 7 also reported detailed data regarding the AVM obliteration rate over time as a function of treatment volume. They noted that the obliteration rate at 1 year did appear to depend upon the nidus volume, but the 2-year obliteration rate appeared to be independent of the nidus volume. Our own results using the gamma unit showed that only the smallest AVMs (volume ≤ 1.0 cm 3 ) had a 100% obliteration rate within 1 or 2 years after treatment.
The effects of factors other than AVM volume such as radiation dose, number of treatment isocenters, and completeness of coverage by the irradiation field on the AVM obliteration rate have also been analyzed. 11 Some of these factors are interrelated, and not easily dissected apart, especially when comparing different treatment modalities (gamma unit vs. LINAC). Still, the radiosurgical dose administered to the margin of all AVMs in our series larger than 3.0 cm in diameter (volume ≥ 14.1 cm 3 ) was 16 Gy, similar to the mean treatment dose of 16.5 Gy reported by Friedman and Bova. 7 Whereas our mean treatment dose (18 Gy) was higher than that reported by Friedman and Bova, the mean treatment dose in the Pittsburgh series was still higher (20.1 Gy). Given the limitations of the available data, we believe that a radiosurgical treatment dose of 16 Gy appears to be just as effective as higher doses in causing obliteration of medium-sized and larger AVMs with volumes greater than 10 cm 3 . Dose homogeneity also may not be crucial to achieve comparable treatment efficacy and safety. In our series, multiple irradiation isocenters (mean four, range one-11) were used to make the treatment isodose (usually the 50% line) conform optimally to the AVM outlines. So, even though our treatment dose at the margin was similar to that used by others utilizing a LINAC system to treat a given AVM volume, the maximum central dose in our patients frequently was higher by as much as 8 to 15 Gy. Although one must exercise caution in interpreting these data, we believe that the radiation dose gradient between the AVM margin and the center of the nidus was not important with respect to the long-term obliteration rate or the incidence of treatment-induced toxicity.
Implications for Multimodality AVM Management
Management strategies for patients with AVMs sometimes include endovascular embolization. However, embolization procedures expose the patient to additional neurological risk beyond that associated with microsurgery or radiosurgery alone. Early in our experience we performed partial embolization of high-risk multicompartmental AVMs larger than 3.0 cm in average diameter in an effort to reduce one or more dimensions of the nidus to proportions more amenable to radiosurgical treatment. Now that primary radiosurgical treatment of selected larger AVMs appears to be feasible, embolization most likely will have a diminished role. Likewise, deliberately staged radiosurgical treatment in two or more sessions, separated by months or years, probably will be undertaken less frequently in the future.
Analysis of the dose plans in cases where the AVM failed to obliterate completely after 3 years often revealed that a portion of the nidus was not covered by the prescribed treatment volume. All such patients, plus those whose treatments were staged deliberately, have required a second treatment session; one patient underwent elective open surgery. This experience has made us even more diligent in our efforts to cover the entire AVM nidus during the initial dose-planning process. As illustrated in Fig. 2 , the response of most AVMs, regardless of size, appeared to be complete by 3 years after treatment. These data support the practice of waiting 3 years before considering any further treatment of an AVM that was covered completely by the prescription isodose. The data also suggest that additional treatment should be considered sooner on an individual basis for AVMs found to have been incompletely covered by the prescribed isodose.
Conclusions
Our preliminary observation that the obliteration rate of most AVMs appeared to be independent of nidus volume has challenged the notion of a 2.5-to 3.0-cm size limit for AVM radiosurgery. Likewise, notions regarding the sufficient dose to obliterate an AVM, previously thought to be 20 to 25 Gy delivered to the margin, have not withstood the test of time. In our experience and in that of others, a lower dose has been sufficient to obliterate many AVMs. Although nidus size, AVM volume, and radiosurgical dose of 20 Gy or greater were not as important predictors of success as originally thought, complete coverage of the AVM by the prescribed dose still appeared to be essential to cause eventual obliteration. The time course of radiosurgically induced AVM shrinkage appeared to be complete by 3 years. However, larger AVMs demonstrated a somewhat delayed response to treatment.
The notion that safe treatment of larger AVMs would require the radiosurgical dose to be reduced to ineffective levels has also been challenged. The radiation-induced complication rate for AVMs greater than 10 cm 3 in our series was no different from that for smaller lesions. The cases in which complete AVM coverage with a nominally sufficient radiosurgical dose still failed to obliterate the AVM have continued to elude a universally accepted explanation. Once technical factors and human error have been minimized or eliminated, one is left to consider factors related to the AVM itself as the cause for failure. Further study of larger numbers of patients, perhaps gathered from multiple institutions, may reveal imaging features or other more subtle characteristics of AVMs that would be of additional prognostic value.
In conclusion, the practice of AVM radiosurgery has evolved as experience with the technique has grown. Ra-diosurgery should be considered an acceptable treatment for selected patients with AVMs of the brain, including some of those who were thought to have been unsuitable for treatment a few years ago.
